Curated News
By: NewsRamp Editorial Staff
October 13, 2026
NanoViricides Advances Ebola Treatment Trial with NV-387 Oral Gummies
TLDR
- NanoViricides advances NV-387 into Phase IIA for Ebola, gaining a potential first-mover advantage in broad-spectrum antiviral development.
- NanoViricides is conducting a Phase IIA trial of NV-387 Oral Gummies in up to 20 Ebola patients to assess safety and tolerability over six to 12 days.
- NanoViricides' trial of NV-387 offers hope for treating Ebola in the Democratic Republic of Congo, potentially improving global health outcomes.
- NanoViricides' NV-387 is a broad-spectrum antiviral that targets host-cell features, and it is being tested as oral gummies for Ebola.
Impact - Why it Matters
The progression of NanoViricides' NV-387 into Phase IIA trials for Ebola Bundibugyo virus marks a significant step in developing a broad-spectrum antiviral that could address multiple viral threats. If successful, NV-387 could offer a much-needed treatment option for Ebola, a disease with high mortality rates and limited therapeutic choices, particularly in outbreak settings like the Democratic Republic of Congo. Moreover, the platform technology behind NV-387 holds promise for combating other viruses such as RSV, COVID-19, and influenza, potentially revolutionizing antiviral therapy by targeting host-cell features rather than the virus itself. This approach could lead to treatments that are less susceptible to viral mutations and resistance, providing a durable solution against emerging viral diseases. Investors and public health officials should monitor these developments closely, as they could impact global health preparedness and response strategies.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial of NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial aims to enroll up to 20 patients with varying disease severity and is assessing the safety and tolerability of treatment regimens lasting six to 12 days. While the study is not designed to establish statistically significant efficacy, it may identify preliminary signs of antiviral activity. Upon completion and evaluation, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study if the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection.
NanoViricides, Inc. (www.nanoviricides.com) is developing special purpose nanomaterials for antiviral therapy. Its novel nanoviricide™ class of drug candidates is based on intellectual property from TheraCour Pharma, Inc., with which it has a Memorandum of Understanding for drug development. The company’s lead candidate, NV-387, is being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Other candidates include NV-HHV-1 for Shingles and NV-CoV-2 for COVID-19. NanoViricides holds broad exclusive licenses from TheraCour for several viral diseases, including HIV, Hepatitis, Rabies, Herpes, Influenza, Dengue, and Ebola. The company continues to advance its pipeline and has a newsroom at https://nnw.fm/NNVC for updates.
NetworkNewsWire, a specialized communications platform, distributed this news as part of its services. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, providing wire solutions, syndication, press release enhancement, social media distribution, and corporate communications. For more information, visit https://www.NetworkNewsWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances Ebola Treatment Trial with NV-387 Oral Gummies
